Methods and compositions for treating lupus

Patent metadata

Field	Value
Publication number	US-9617343-B2
Application number	US-201013320001-A
Country	US
Kind code	B2
Filing date	May 13, 2010
Priority date	May 13, 2009
Publication date	Apr 11, 2017
Grant date	Apr 11, 2017

Abstract

The invention provides methods of treating lupus in a patient with an anti-CD52 antibody. Also includes are methods of increasing infiltration of regulatory T cells to affected sides of the patient's body, methods of reducing urine protein and/or albumin levels and methods of depleting lymphocytes to alleviate lupus symptoms.

First claim

What is claimed is:

1. A method of increasing FoxP3 + regulatory T cells in a patient with lupus, comprising
selecting a patient for treatment for lupus, and
administering to the patient in vivo antibody therapy consisting of administration of an anti-CD52 monoclonal antibody, wherein the anti-CD52 monoclonal antibody increases FoxP3 + regulatory T cells in the patient,
wherein the method does not include ex vivo expansion of T cells to produce regulatory T cells,
thereby treating lupus in the patient.

2. The method of claim 1 , wherein the method further comprises administering to the patient an agent that stimulates said regulatory T cells.

3. The method of claim 2 , wherein the agent is rapamycin, a TGF-β, IL-10, IL-4, IFN-α, vitamin D3, dexamethasone, or mycophenolate mofetil.

4. The method of claim 3 , wherein the TGF-β is an active or latent form of any one of TGF-β1, TGF-β2, TGF-β3, TGF-β4, and TGF-β5.

5. The method of claim 1 , wherein said regulatory T cells are increased at least at one site of inflammation.

6. The method of claim 5 , wherein the site of inflammation is blood, central nervous system (CNS), heart, liver, joint, kidney, lung, skin, intestinal tract, or vasculature.

7. The method of claim 1 , wherein the anti-CD52 monoclonal antibody reduces the level of urine protein, or urine albumin, or both, in the patient.

8. The method of claim 7 , wherein the patient is a human.

9. The method of claim 7 , wherein the anti-CD52 monoclonal antibody is a humanized or human anti-CD52 monoclonal antibody.

10. The method of claim 9 , wherein the antibody is alemtuzumab.

11. The method of claim 1 , wherein the patient is a human.

12. The method of claim 1 , wherein the anti-CD52 monoclonal antibody is a humanized or human anti-human CD52 monoclonal antibody.

13. The method of claim 12 , wherein the antibody is alemtuzumab.

14. The method of claim 1 , wherein the anti-CD52 monoclonal antibody is administered in a monotherapy.

15. The method of claim 14 , wherein said regulatory T cells are increased at least at one site of inflammation.

16. The method of claim 14 , wherein the patient is a human and wherein the anti-CD52 monoclonal antibody is a humanized or human anti-human CD52 monoclonal antibody.

17. The method of claim 16 , wherein the antibody is alemtuzumab.

Assignees

• Kaplan Johanne M
• Roberts Bruce L
• Siders William M
• Genzyme Corp

Inventors

• Kaplan Johanne M
• Roberts Bruce L
• Siders William M

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P7/00

  Drugs for disorders of the blood or the extracellular fluid · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title